



## Advantage CropAmmo Ballance Agri-Nutrients

Chemwatch: 5474-27

Version No: 2.1.3.7

Safety Data Sheet according to the Health and Safety at Work (Hazardous Substances) Regulations 2017

Chemwatch Hazard Alert Code: 3

Issue Date: 21/06/2021

Print Date: 22/06/2021

L.GHS.NZL.EN

### SECTION 1 Identification of the substance / mixture and of the company / undertaking

#### Product Identifier

Product name	Advantage CropAmmo
Chemical Name	Not Applicable
Chemical formula	Not Applicable
Other means of identification	Not Available

#### Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	Fertiliser.
--------------------------	-------------

#### Details of the supplier of the safety data sheet

Registered company name	Ballance Agri-Nutrients
Address	161 Hewletts Rd Mount Maunganui New Zealand
Telephone	+64 800 222 090
Fax	Not Available
Website	Not Available
Email	customerservices-mount@ballance.co.nz

#### Emergency telephone number

Association / Organisation	CHEMCALL
Emergency telephone numbers	Freephone: 0800 CHEMCALL (0800 243 622) (24 Hours/ 7 Days)
Other emergency telephone numbers	Not Available

### SECTION 2 Hazards identification

#### Classification of the substance or mixture

**Considered a Hazardous Substance according to the criteria of the New Zealand Hazardous Substances New Organisms legislation. Not regulated for transport of Dangerous Goods.**

#### ChemWatch Hazard Ratings



	Min	Max
Flammability	1	1
Toxicity	1	1
Body Contact	3	3
Reactivity	1	1
Chronic	3	3

0 = Minimum  
1 = Low  
2 = Moderate  
3 = High  
4 = Extreme

Classification [1]	Acute Toxicity (Oral) Category 4, Skin Sensitizer Category 1, Eye Irritation Category 2, Reproductive Toxicity Category 1, Acute Vertebrate Hazard Category 3
Legend:	1. Classified by Chemwatch; 2. Classification drawn from CCID EPA NZ; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI
Determined by Chemwatch using GHS/HSNO criteria	6.1D (oral), 6.4A, 6.5B (contact), 6.8A, 9.3C

#### Label elements

## Advantage CropAmmo

Hazard pictogram(s)	 
---------------------	---

Signal word	Danger
-------------	--------

### Hazard statement(s)

H302	Harmful if swallowed.
H317	May cause an allergic skin reaction.
H319	Causes serious eye irritation.
H360	May damage fertility or the unborn child.
H433	Harmful to terrestrial vertebrates.

### Precautionary statement(s) Prevention

P201	Obtain special instructions before use.
P280	Wear protective gloves, protective clothing, eye protection and face protection.
P261	Avoid breathing dust/fumes.
P264	Wash all exposed external body areas thoroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P272	Contaminated work clothing should not be allowed out of the workplace.

### Precautionary statement(s) Response

P308+P313	IF exposed or concerned: Get medical advice/ attention.
P302+P352	IF ON SKIN: Wash with plenty of water.
P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P333+P313	If skin irritation or rash occurs: Get medical advice/attention.
P337+P313	If eye irritation persists: Get medical advice/attention.
P362+P364	Take off contaminated clothing and wash it before reuse.
P301+P312	IF SWALLOWED: Call a POISON CENTER/doctor/physician/first aider if you feel unwell.
P330	Rinse mouth.

### Precautionary statement(s) Storage

P405	Store locked up.
------	------------------

### Precautionary statement(s) Disposal

P501	Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.
------	--

## SECTION 3 Composition / information on ingredients

### Substances

See section below for composition of Mixtures

### Mixtures

CAS No	%[weight]	Name
57-13-6	30-60	<u>urea</u>
7783-20-2	10-30	<u>ammonium sulfate</u>
57-55-6	<1	<u>propylene glycol</u>
94317-64-3	<1	<u>N-(n-butyl)thiophosphoric triamide</u>
872-50-4	<1	<u>N-methyl-2-pyrrolidone</u>
Not Available	balance	Ingredients determined not to be hazardous
<b>Legend:</b> 1. Classified by Chemwatch; 2. Classification drawn from CCID EPA NZ; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L; * EU IOELVs available		

## SECTION 4 First aid measures

### Description of first aid measures

Eye Contact	<p>If this product comes in contact with the eyes:</p> <ul style="list-style-type: none"> <li>▶ Immediately hold eyelids apart and flush the eye continuously with running water.</li> <li>▶ Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.</li> <li>▶ Continue flushing until advised to stop by the Poisons Information Centre or a doctor, or for at least 15 minutes.</li> <li>▶ Transport to hospital or doctor without delay.</li> <li>▶ Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.</li> </ul>
-------------	--

Continued...

## Advantage CropAmmo

<b>Skin Contact</b>	<p>If skin contact occurs:</p> <ul style="list-style-type: none"> <li>▶ Immediately remove all contaminated clothing, including footwear.</li> <li>▶ Flush skin and hair with running water (and soap if available).</li> <li>▶ Seek medical attention in event of irritation.</li> </ul>
<b>Inhalation</b>	<ul style="list-style-type: none"> <li>▶ If fumes or combustion products are inhaled remove from contaminated area.</li> <li>▶ Lay patient down. Keep warm and rested.</li> <li>▶ Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures.</li> <li>▶ Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary.</li> <li>▶ Transport to hospital, or doctor, without delay.</li> </ul>
<b>Ingestion</b>	<ul style="list-style-type: none"> <li>▶ <b>IF SWALLOWED, REFER FOR MEDICAL ATTENTION, WHERE POSSIBLE, WITHOUT DELAY.</b></li> <li>▶ For advice, contact a Poisons Information Centre or a doctor.</li> <li>▶ Urgent hospital treatment is likely to be needed.</li> <li>▶ In the mean time, qualified first-aid personnel should treat the patient following observation and employing supportive measures as indicated by the patient's condition.</li> <li>▶ If the services of a medical officer or medical doctor are readily available, the patient should be placed in his/her care and a copy of the SDS should be provided. Further action will be the responsibility of the medical specialist.</li> <li>▶ If medical attention is not available on the worksite or surroundings send the patient to a hospital together with a copy of the SDS.</li> </ul> <p><b>Where medical attention is not immediately available or where the patient is more than 15 minutes from a hospital or unless instructed otherwise:</b></p> <ul style="list-style-type: none"> <li>▶ <b>INDUCE</b> vomiting with fingers down the back of the throat, <b>ONLY IF CONSCIOUS</b>. Lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration.</li> </ul> <p><b>NOTE:</b> Wear a protective glove when inducing vomiting by mechanical means.</p>

### Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

## SECTION 5 Firefighting measures

### Extinguishing media

- ▶ There is no restriction on the type of extinguisher which may be used.
- ▶ Use extinguishing media suitable for surrounding area.

### Special hazards arising from the substrate or mixture

<b>Fire Incompatibility</b>	▶ Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result
-----------------------------	--

### Advice for firefighters

<b>Fire Fighting</b>	<ul style="list-style-type: none"> <li>▶ Alert Fire Brigade and tell them location and nature of hazard.</li> <li>▶ Wear breathing apparatus plus protective gloves in the event of a fire.</li> <li>▶ Prevent, by any means available, spillage from entering drains or water courses.</li> <li>▶ Use fire fighting procedures suitable for surrounding area.</li> <li>▶ <b>DO NOT</b> approach containers suspected to be hot.</li> <li>▶ Cool fire exposed containers with water spray from a protected location.</li> <li>▶ If safe to do so, remove containers from path of fire.</li> <li>▶ Equipment should be thoroughly decontaminated after use.</li> </ul>
<b>Fire/Explosion Hazard</b>	<ul style="list-style-type: none"> <li>▶ Solid which exhibits difficult combustion or is difficult to ignite.</li> <li>▶ Avoid generating dust, particularly clouds of dust in a confined or unventilated space as dusts may form an explosive mixture with air, and any source of ignition, i.e. flame or spark, will cause fire or explosion.</li> <li>▶ Dust clouds generated by the fine grinding of the solid are a particular hazard; accumulations of fine dust (420 micron or less) may burn rapidly and fiercely if ignited; once initiated larger particles up to 1400 microns diameter will contribute to the propagation of an explosion.</li> <li>▶ A dust explosion may release large quantities of gaseous products; this in turn creates a subsequent pressure rise of explosive force capable of damaging plant and buildings and injuring people.</li> <li>▶ Usually the initial or primary explosion takes place in a confined space such as plant or machinery, and can be of sufficient force to damage or rupture the plant. If the shock wave from the primary explosion enters the surrounding area, it will disturb any settled dust layers, forming a second dust cloud, and often initiate a much larger secondary explosion. All large scale explosions have resulted from chain reactions of this type.</li> <li>▶ Dry dust can also be charged electrostatically by turbulence, pneumatic transport, pouring, in exhaust ducts and during transport.</li> <li>▶ Build-up of electrostatic charge may be prevented by bonding and grounding.</li> <li>▶ Powder handling equipment such as dust collectors, dryers and mills may require additional protection measures such as explosion venting.</li> <li>▶ All movable parts coming in contact with this material should have a speed of less than 1-metre/sec.</li> </ul> <p>Decomposes on heating and produces:  carbon monoxide (CO)  carbon dioxide (CO<sub>2</sub>)  nitrogen oxides (NO<sub>x</sub>)  phosphorus oxides (PO<sub>x</sub>)  sulfur oxides (SO<sub>x</sub>)  other pyrolysis products typical of burning organic material.</p> <p>In fire situation urea melts and flows, on further heating it decomposes giving off ammonia gas. Thermal and oxidative degradation products can include ammonia, biuret, and cyanuric acid,.  May emit poisonous fumes.  May emit corrosive fumes.</p>

## SECTION 6 Accidental release measures

### Personal precautions, protective equipment and emergency procedures

See section 8

Continued...

## Advantage CropAmmo

### Environmental precautions

See section 12

### Methods and material for containment and cleaning up

<b>Minor Spills</b>	<ul style="list-style-type: none"> <li>▶ Remove all ignition sources.</li> <li>▶ Clean up all spills immediately.</li> <li>▶ Avoid contact with skin and eyes.</li> <li>▶ Control personal contact with the substance, by using protective equipment.</li> <li>▶ Use dry clean up procedures and avoid generating dust.</li> <li>▶ Place in a suitable, labelled container for waste disposal.</li> </ul>
<b>Major Spills</b>	<p>Moderate hazard.</p> <ul style="list-style-type: none"> <li>▶ <b>CAUTION:</b> Advise personnel in area.</li> <li>▶ Alert Emergency Services and tell them location and nature of hazard.</li> <li>▶ Control personal contact by wearing protective clothing.</li> <li>▶ Prevent, by any means available, spillage from entering drains or water courses.</li> <li>▶ Recover product wherever possible.</li> <li>▶ <b>IF DRY:</b> Use dry clean up procedures and avoid generating dust. Collect residues and place in sealed plastic bags or other containers for disposal. <b>IF WET:</b> Vacuum/shovel up and place in labelled containers for disposal.</li> <li>▶ <b>ALWAYS:</b> Wash area down with large amounts of water and prevent runoff into drains.</li> <li>▶ If contamination of drains or waterways occurs, advise Emergency Services.</li> </ul>

Personal Protective Equipment advice is contained in Section 8 of the SDS.

## SECTION 7 Handling and storage

### Precautions for safe handling

<b>Safe handling</b>	<ul style="list-style-type: none"> <li>▶ Avoid all personal contact, including inhalation.</li> <li>▶ Wear protective clothing when risk of exposure occurs.</li> <li>▶ Use in a well-ventilated area.</li> <li>▶ Prevent concentration in hollows and sumps.</li> <li>▶ <b>DO NOT enter confined spaces until atmosphere has been checked.</b></li> <li>▶ <b>DO NOT allow material to contact humans, exposed food or food utensils.</b></li> <li>▶ Avoid contact with incompatible materials.</li> <li>▶ <b>When handling, DO NOT eat, drink or smoke.</b></li> <li>▶ Keep containers securely sealed when not in use.</li> <li>▶ Avoid physical damage to containers.</li> <li>▶ Always wash hands with soap and water after handling.</li> <li>▶ Work clothes should be laundered separately. Launder contaminated clothing before re-use.</li> <li>▶ Use good occupational work practice.</li> <li>▶ Observe manufacturer's storage and handling recommendations contained within this SDS.</li> <li>▶ Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.</li> <li>▶ Organic powders when finely divided over a range of concentrations regardless of particulate size or shape and suspended in air or some other oxidizing medium may form explosive dust-air mixtures and result in a fire or dust explosion (including secondary explosions)</li> <li>▶ Minimise airborne dust and eliminate all ignition sources. Keep away from heat, hot surfaces, sparks, and flame.</li> <li>▶ Establish good housekeeping practices.</li> <li>▶ Remove dust accumulations on a regular basis by vacuuming or gentle sweeping to avoid creating dust clouds.</li> <li>▶ Use continuous suction at points of dust generation to capture and minimise the accumulation of dusts. Particular attention should be given to overhead and hidden horizontal surfaces to minimise the probability of a "secondary" explosion. According to NFPA Standard 654, dust layers 1/32 in.(0.8 mm) thick can be sufficient to warrant immediate cleaning of the area.</li> <li>▶ Do not use air hoses for cleaning.</li> <li>▶ Minimise dry sweeping to avoid generation of dust clouds. Vacuum dust-accumulating surfaces and remove to a chemical disposal area. Vacuums with explosion-proof motors should be used.</li> <li>▶ Control sources of static electricity. Dusts or their packages may accumulate static charges, and static discharge can be a source of ignition.</li> <li>▶ Solids handling systems must be designed in accordance with applicable standards (e.g. NFPA including 654 and 77) and other national guidance.</li> <li>▶ Do not empty directly into flammable solvents or in the presence of flammable vapors.</li> <li>▶ The operator, the packaging container and all equipment must be grounded with electrical bonding and grounding systems. Plastic bags and plastics cannot be grounded, and antistatic bags do not completely protect against development of static charges.</li> </ul> <p>Empty containers may contain residual dust which has the potential to accumulate following settling. Such dusts may explode in the presence of an appropriate ignition source.</p> <ul style="list-style-type: none"> <li>▶ <b>Do NOT cut, drill, grind or weld such containers.</b></li> <li>▶ In addition ensure such activity is not performed near full, partially empty or empty containers without appropriate workplace safety authorisation or permit.</li> </ul>
<b>Other information</b>	<ul style="list-style-type: none"> <li>▶ Store in original containers.</li> <li>▶ Keep containers securely sealed.</li> <li>▶ Store in a cool, dry area protected from environmental extremes.</li> <li>▶ Store away from incompatible materials and foodstuff containers.</li> <li>▶ Protect containers against physical damage and check regularly for leaks.</li> <li>▶ Observe manufacturer's storage and handling recommendations contained within this SDS.</li> </ul> <p>For major quantities:</p> <ul style="list-style-type: none"> <li>▶ Consider storage in bunded areas - ensure storage areas are isolated from sources of community water (including stormwater, ground water, lakes and streams).</li> <li>▶ Ensure that accidental discharge to air or water is the subject of a contingency disaster management plan; this may require consultation with local authorities.</li> </ul>

### Conditions for safe storage, including any incompatibilities

<b>Suitable container</b>	<ul style="list-style-type: none"> <li>▶ Glass container is suitable for laboratory quantities</li> <li>▶ Polyethylene or polypropylene container.</li> <li>▶ Check all containers are clearly labelled and free from leaks.</li> </ul>
<b>Storage incompatibility</b>	<ul style="list-style-type: none"> <li>▶ Avoid strong bases.</li> <li>▶ Avoid reaction with oxidising agents</li> </ul>

Continued...



X — Must not be stored together  
O — May be stored together with specific preventions  
+ — May be stored together

Note: Depending on other risk factors, compatibility assessment based on the table above may not be relevant to storage situations, particularly where large volumes of dangerous goods are stored and handled. Reference should be made to the Safety Data Sheets for each substance or article and risks assessed accordingly.

SECTION 8 Exposure controls / personal protection

Control parameters

Occupational Exposure Limits (OEL)

INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
New Zealand Workplace Exposure Standards (WES)	propylene glycol	Propane-1,2-diol: Vapour and particulates	150 ppm / 474 mg/m3	Not Available	Not Available	Not Available
New Zealand Workplace Exposure Standards (WES)	propylene glycol	Propane-1,2-diol: Particulates only	10 mg/m3	Not Available	Not Available	Not Available
New Zealand Workplace Exposure Standards (WES)	N-methyl-2-pyrrolidone	1-Methyl-2-pyrrolidone	25 ppm / 103 mg/m3	309 mg/m3 / 75 ppm	Not Available	skin-Skin absorption

Emergency Limits

Ingredient	TEEL-1	TEEL-2	TEEL-3
urea	30 mg/m3	280 mg/m3	1,700 mg/m3
ammonium sulfate	13 mg/m3	140 mg/m3	840 mg/m3
propylene glycol	30 mg/m3	330 mg/m3	2,000 mg/m3
propylene glycol	30 mg/m3	1,300 mg/m3	7,900 mg/m3
N-methyl-2-pyrrolidone	30 ppm	32 ppm	190 ppm

Ingredient	Original IDLH	Revised IDLH
urea	Not Available	Not Available
ammonium sulfate	Not Available	Not Available
propylene glycol	Not Available	Not Available
N-(n-butyl)thiophosphoric triamide	Not Available	Not Available
N-methyl-2-pyrrolidone	Not Available	Not Available

Occupational Exposure Banding

Ingredient	Occupational Exposure Band Rating	Occupational Exposure Band Limit
urea	E	≤ 0.01 mg/m³
ammonium sulfate	E	≤ 0.01 mg/m³
N-(n-butyl)thiophosphoric triamide	E	≤ 0.01 mg/m³

**Notes:** Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a range of exposure concentrations that are expected to protect worker health.

MATERIAL DATA

Exposure controls

Appropriate engineering controls	<p>Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection.</p> <p>The basic types of engineering controls are:</p> <ul style="list-style-type: none"><li>Process controls which involve changing the way a job activity or process is done to reduce the risk.</li><li>Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use.</li><li>Employers may need to use multiple types of controls to prevent employee overexposure.</li></ul> <p>► Local exhaust ventilation is required where solids are handled as powders or crystals; even when particulates are relatively large, a certain proportion will be powdered by mutual friction.</p> <p>► If in spite of local exhaust an adverse concentration of the substance in air could occur, respiratory protection should be considered.</p> <p>Such protection might consist of:</p> <ul style="list-style-type: none"><li>(a): particle dust respirators, if necessary, combined with an absorption cartridge;</li><li>(b): filter respirators with absorption cartridge or canister of the right type;</li><li>(c): fresh-air hoods or masks.</li></ul> <p>Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.</p> <p>Type of Contaminant: _____ Air Speed: _____</p>
----------------------------------	--

## Advantage CropAmmo

	<p>direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)</p> <p>grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion).</p> <p>Within each range the appropriate value depends on:</p> <table><tr><th>Lower end of the range</th><th>Upper end of the range</th></tr><tr><td>1: Room air currents minimal or favourable to capture</td><td>1: Disturbing room air currents</td></tr><tr><td>2: Contaminants of low toxicity or of nuisance value only.</td><td>2: Contaminants of high toxicity</td></tr><tr><td>3: Intermittent, low production.</td><td>3: High production, heavy use</td></tr><tr><td>4: Large hood or large air mass in motion</td><td>4: Small hood-local control only</td></tr></table> <p>Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 4-10 m/s (800-2000 f/min) for extraction of crusher dusts generated 2 metres distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.</p>	Lower end of the range	Upper end of the range	1: Room air currents minimal or favourable to capture	1: Disturbing room air currents	2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of high toxicity	3: Intermittent, low production.	3: High production, heavy use	4: Large hood or large air mass in motion	4: Small hood-local control only	<p>1-2.5 m/s (200-500 f/min.)</p> <p>2.5-10 m/s (500-2000 f/min.)</p>
Lower end of the range	Upper end of the range											
1: Room air currents minimal or favourable to capture	1: Disturbing room air currents											
2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of high toxicity											
3: Intermittent, low production.	3: High production, heavy use											
4: Large hood or large air mass in motion	4: Small hood-local control only											
Personal protection												
Eye and face protection	<ul style="list-style-type: none"><li>▶ Safety glasses with side shields.</li><li>▶ Chemical goggles.</li><li>▶ Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent]</li></ul>											
Skin protection	See Hand protection below											
Hands/feet protection	<p><b>NOTE:</b></p> <ul style="list-style-type: none"><li>▶ The material may produce skin sensitisation in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact.</li><li>▶ Contaminated leather items, such as shoes, belts and watch-bands should be removed and destroyed.</li></ul> <p>The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to manufacturer. Where the chemical is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.</p> <p>The exact break through time for substances has to be obtained from the manufacturer of the protective gloves and has to be observed when making a final choice.</p> <p>Personal hygiene is a key element of effective hand care. Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.</p> <p>Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include:</p> <ul style="list-style-type: none"><li>• frequency and duration of contact,</li><li>• chemical resistance of glove material,</li><li>• glove thickness and</li><li>• dexterity</li></ul> <p>Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739, AS/NZS 2161.1 or national equivalent).</p> <ul style="list-style-type: none"><li>• When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended.</li><li>• When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended.</li><li>• Some glove polymer types are less affected by movement and this should be taken into account when considering gloves for long-term use.</li><li>• Contaminated gloves should be replaced.</li></ul> <p>As defined in ASTM F-739-96 in any application, gloves are rated as:</p> <ul style="list-style-type: none"><li>• Excellent when breakthrough time &gt; 480 min</li><li>• Good when breakthrough time &gt; 20 min</li><li>• Fair when breakthrough time &lt; 20 min</li><li>• Poor when glove material degrades</li></ul> <p>For general applications, gloves with a thickness typically greater than 0.35 mm, are recommended.</p> <p>It should be emphasised that glove thickness is not necessarily a good predictor of glove resistance to a specific chemical, as the permeation efficiency of the glove will be dependent on the exact composition of the glove material. Therefore, glove selection should also be based on consideration of the task requirements and knowledge of breakthrough times.</p> <p>Glove thickness may also vary depending on the glove manufacturer, the glove type and the glove model. Therefore, the manufacturers' technical data should always be taken into account to ensure selection of the most appropriate glove for the task.</p> <p>Note: Depending on the activity being conducted, gloves of varying thickness may be required for specific tasks. For example:</p> <ul style="list-style-type: none"><li>• Thinner gloves (down to 0.1 mm or less) may be required where a high degree of manual dexterity is needed. However, these gloves are only likely to give short duration protection and would normally be just for single use applications, then disposed of.</li><li>• Thicker gloves (up to 3 mm or more) may be required where there is a mechanical (as well as a chemical) risk i.e. where there is abrasion or puncture potential</li></ul> <p>Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.</p> <p>Experience indicates that the following polymers are suitable as glove materials for protection against undissolved, dry solids, where abrasive particles are not present.</p> <ul style="list-style-type: none"><li>▶ polychloroprene.</li><li>▶ nitrile rubber.</li><li>▶ butyl rubber.</li><li>▶ fluorocautchouc.</li><li>▶ polyvinyl chloride.</li></ul> <p>Gloves should be examined for wear and/ or degradation constantly.</p>											

## Advantage CropAmmo

<b>Body protection</b>	See Other protection below
<b>Other protection</b>	<ul style="list-style-type: none"> <li>▶ Overalls.</li> <li>▶ P.V.C apron.</li> <li>▶ Barrier cream.</li> <li>▶ Skin cleansing cream.</li> <li>▶ Eye wash unit.</li> </ul>

### Recommended material(s)

#### GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:

**"Forsberg Clothing Performance Index".**

The effect(s) of the following substance(s) are taken into account in the **computer-generated** selection:

Advantage CropAmmo

Material	CPI
PE/EVAL/PE	A
BUTYL	C
NATURAL RUBBER	C
PVA	C

\* CPI - Chemwatch Performance Index

A: Best Selection

B: Satisfactory; may degrade after 4 hours continuous immersion

C: Poor to Dangerous Choice for other than short term immersion

**NOTE:** As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -

\* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

### Respiratory protection

Type AK-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 10 x ES	AK P1 Air-line*	-	AK PAPR-P1 -
up to 50 x ES	Air-line**	AK P2	AK PAPR-P2
up to 100 x ES	-	AK P3	-
		Air-line*	-
100+ x ES	-	Air-line**	AK PAPR-P3

\* - Negative pressure demand \*\* - Continuous flow

A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

- Respirators may be necessary when engineering and administrative controls do not adequately prevent exposures.
  - The decision to use respiratory protection should be based on professional judgment that takes into account toxicity information, exposure measurement data, and frequency and likelihood of the worker's exposure - ensure users are not subject to high thermal loads which may result in heat stress or distress due to personal protective equipment (powered, positive flow, full face apparatus may be an option).
  - Published occupational exposure limits, where they exist, will assist in determining the adequacy of the selected respiratory protection. These may be government mandated or vendor recommended.
  - Certified respirators will be useful for protecting workers from inhalation of particulates when properly selected and fit tested as part of a complete respiratory protection program.
  - Where protection from nuisance levels of dusts are desired, use type N95 (US) or type P1 (EN143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU)
  - Use approved positive flow mask if significant quantities of dust becomes airborne.
  - Try to avoid creating dust conditions.
- Class P2 particulate filters are used for protection against mechanically and thermally generated particulates or both.
- P2 is a respiratory filter rating under various international standards, Filters at least 94% of airborne particles
- Suitable for:
- Relatively small particles generated by mechanical processes eg. grinding, cutting, sanding, drilling, sawing.
  - Sub-micron thermally generated particles e.g. welding fumes, fertilizer and bushfire smoke.
  - Biologically active airborne particles under specified infection control applications e.g. viruses, bacteria, COVID-19, SARS

## SECTION 9 Physical and chemical properties

### Information on basic physical and chemical properties

<b>Appearance</b>	Coloured granules; partly mixes with water.		
<b>Physical state</b>	Divided Solid	<b>Relative density (Water = 1)</b>	Not Available
<b>Odour</b>	Not Available	<b>Partition coefficient n-octanol / water</b>	Not Available
<b>Odour threshold</b>	Not Available	<b>Auto-ignition temperature (°C)</b>	Not Applicable
<b>pH (as supplied)</b>	Not Available	<b>Decomposition temperature</b>	Not Available
<b>Melting point / freezing point (°C)</b>	Not Available	<b>Viscosity (cSt)</b>	Not Applicable
<b>Initial boiling point and boiling range (°C)</b>	Not Applicable	<b>Molecular weight (g/mol)</b>	Not Applicable
<b>Flash point (°C)</b>	Not Applicable	<b>Taste</b>	Not Available
<b>Evaporation rate</b>	Not Available	<b>Explosive properties</b>	Not Available
<b>Flammability</b>	Not Applicable	<b>Oxidising properties</b>	Not Available
<b>Upper Explosive Limit (%)</b>	Not Applicable	<b>Surface Tension (dyn/cm or mN/m)</b>	Not Applicable

Continued...



## Advantage CropAmmo

<b>Lower Explosive Limit (%)</b>	Not Applicable	<b>Volatile Component (%vol)</b>	Not Available
<b>Vapour pressure (kPa)</b>	Not Applicable	<b>Gas group</b>	Not Available
<b>Solubility in water</b>	Partly miscible	<b>pH as a solution (%)</b>	Not Available
<b>Vapour density (Air = 1)</b>	Not Available	<b>VOC g/L</b>	Not Available

### SECTION 10 Stability and reactivity

<b>Reactivity</b>	See section 7
<b>Chemical stability</b>	<ul style="list-style-type: none"> <li>Unstable in the presence of incompatible materials.</li> <li>Product is considered stable.</li> <li>Hazardous polymerisation will not occur.</li> </ul>
<b>Possibility of hazardous reactions</b>	See section 7
<b>Conditions to avoid</b>	See section 7
<b>Incompatible materials</b>	See section 7
<b>Hazardous decomposition products</b>	See section 5

### SECTION 11 Toxicological information

#### Information on toxicological effects

<b>Inhaled</b>	<p>Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.</p> <p>If prior damage to the circulatory or nervous systems has occurred or if kidney damage has been sustained, proper screenings should be conducted on individuals who may be exposed to further risk if handling and use of the material result in excessive exposures.</p> <p>Urea in small quantities is considered to be practically non-harmful by all exposure routes. The dust should be regarded as a nuisance dust and exposure should be kept as low as practical. Confirmed asthmatics should avoid prolonged contact with urea dust. Urea may cause irritation of the respiratory tract. Symptoms may include coughing, shortness of breath. Urea may be absorbed into the bloodstream producing symptoms similar to those caused by ingestion.</p> <p>Limited evidence or practical experience suggests that the material may produce irritation of the respiratory system, in a significant number of individuals, following inhalation. In contrast to most organs, the lung is able to respond to a chemical insult by first removing or neutralising the irritant and then repairing the damage. The repair process, which initially evolved to protect mammalian lungs from foreign matter and antigens, may however, produce further lung damage resulting in the impairment of gas exchange, the primary function of the lungs. Respiratory tract irritation often results in an inflammatory response involving the recruitment and activation of many cell types, mainly derived from the vascular system.</p>
<b>Ingestion</b>	<p>Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual.</p>
<b>Skin Contact</b>	<p>Open cuts, abraded or irritated skin should not be exposed to this material</p> <p>Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.</p> <p>The material may produce mild skin irritation; limited evidence or practical experience suggests, that the material either:</p> <ul style="list-style-type: none"> <li>produces mild inflammation of the skin in a substantial number of individuals following direct contact, and/or</li> <li>produces significant, but mild, inflammation when applied to the healthy intact skin of animals (for up to four hours), such inflammation being present twenty-four hours or more after the end of the exposure period.</li> </ul> <p>Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (non allergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis.</p>
<b>Eye</b>	<p>Evidence exists, or practical experience predicts, that the material may cause eye irritation in a substantial number of individuals and/or may produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals.</p> <p>Repeated or prolonged eye contact may cause inflammation characterised by temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.</p>
<b>Chronic</b>	<p>Practical experience shows that skin contact with the material is capable either of inducing a sensitisation reaction in a substantial number of individuals, and/or of producing a positive response in experimental animals.</p> <p>Substances that can cause occupational asthma (also known as asthmagens and respiratory sensitisers) can induce a state of specific airway hyper-responsiveness via an immunological, irritant or other mechanism. Once the airways have become hyper-responsive, further exposure to the substance, sometimes even to tiny quantities, may cause respiratory symptoms. These symptoms can range in severity from a runny nose to asthma. Not all workers who are exposed to a sensitiser will become hyper-responsive and it is impossible to identify in advance who are likely to become hyper-responsive.</p> <p>Substances that can cause occupational asthma should be distinguished from substances which may trigger the symptoms of asthma in people with pre-existing air-way hyper-responsiveness. The latter substances are not classified as asthmagens or respiratory sensitisers</p> <p>Wherever it is reasonably practicable, exposure to substances that can cause occupational asthma should be prevented. Where this is not possible the primary aim is to apply adequate standards of control to prevent workers from becoming hyper-responsive.</p> <p>Activities giving rise to short-term peak concentrations should receive particular attention when risk management is being considered. Health surveillance is appropriate for all employees exposed or liable to be exposed to a substance which may cause occupational asthma and there should be appropriate consultation with an occupational health professional over the degree of risk and level of surveillance.</p> <p>There is sufficient evidence to establish a causal relationship between human exposure to the material and subsequent developmental toxic effects in the off-spring.</p> <p>Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.</p> <p>Long term exposure to high dust concentrations may cause changes in lung function (i.e. pneumoconiosis) caused by particles less than 0.5 micron penetrating and remaining in the lung. A prime symptom is breathlessness. Lung shadows show on X-ray.</p> <p>High levels of exposure to urea in the Russian workplace have been reported to produce emphysema, a high incidence of protein metabolism disturbances and chronic weight loss.</p> <p>The backs of rats were treated by dermal application with 10%, 20%, 40% urea ointment daily for 4 to 24 weeks. No erythema or other responses</p>

Continued...



### Advantage CropAmmo

	were noted at the application site. At 25 weeks there was a decrease, in the 40% urea ointment group, of brain and prostrate weights. In medicine, avoid urea in cases of renal or hepatic impairment. Urea is excreted as a product of normal body metabolic processes. Levels above 10 ug/m3 of suspended inorganic sulfates in the air may cause an excess risk of asthmatic attacks in susceptible persons	
Advantage CropAmmo	<b>TOXICITY</b>	<b>IRRITATION</b>
	Not Available	Not Available
urea	<b>TOXICITY</b>	<b>IRRITATION</b>
	dermal (rat) LD50: 8200 mg/kg <sup>[2]</sup>	Eye: no adverse effect observed (not irritating) <sup>[1]</sup>
	Oral(Rat) LD50; ~14 mg/kg <sup>[2]</sup>	Skin (human): 22 mg/3 d (I)- mild
		Skin: no adverse effect observed (not irritating) <sup>[1]</sup>
ammonium sulfate	<b>TOXICITY</b>	<b>IRRITATION</b>
	dermal (rat) LD50: >2000 mg/kg <sup>[1]</sup>	Eye: no adverse effect observed (not irritating) <sup>[1]</sup>
	Oral(Mouse) LD50; 610 mg/kg <sup>[2]</sup>	Skin: no adverse effect observed (not irritating) <sup>[1]</sup>
propylene glycol	<b>TOXICITY</b>	<b>IRRITATION</b>
	Dermal (rabbit) LD50: >2000 mg/kg <sup>[1]</sup>	Eye (rabbit): 100 mg - mild
	Inhalation(Rat) LC50; >44.9 mg/L4h <sup>[2]</sup>	Eye (rabbit): 500 mg/24h - mild
	Oral(Rat) LD50; >10400 mg/kg <sup>[2]</sup>	Eye: no adverse effect observed (not irritating) <sup>[1]</sup>
		Skin(human):104 mg/3d Intermit Mod
		Skin(human):500 mg/7days mild
		Skin: no adverse effect observed (not irritating) <sup>[1]</sup>
N-(n-butyl)thiophosphoric triamide	<b>TOXICITY</b>	<b>IRRITATION</b>
	Dermal (rabbit) LD50: >2000 mg/kg <sup>[1]</sup>	Eye (rabbit): slight
	Inhalation(Rat) LC50; >2.1 mg/l4h <sup>[1]</sup>	Eye: adverse effect observed (irritating) <sup>[1]</sup>
	Oral(Rat) LD50; 2000 mg/kg <sup>[1]</sup>	Skin (rabbit): mild sensitiser
		Skin: no adverse effect observed (not irritating) <sup>[1]</sup>
N-methyl-2-pyrrolidone	<b>TOXICITY</b>	<b>IRRITATION</b>
	Dermal (rabbit) LD50: 2000-4000 mg/kg <sup>[2]</sup>	Eye (rabbit): 100 mg - moderate
	Inhalation(Rat) LC50; 3.1-8.8 mg/l4h <sup>[2]</sup>	
	Oral(Rabbit) LD50; ~3500 mg/kg <sup>[2]</sup>	
<b>Legend:</b>	1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2. * Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances	

UREA	<p>Altered sleep time, change in motor activity, antipsychosis, dyspnea, methaemoglobinaemia, convulsions, lymphomas recorded. Carcinogenic by RTECS criteria.</p> <p>The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis.</p> <p>For urea:</p> <p>There is little data that relates urea to human health other than its use in dermatology and some more limited applications in clinical medicine. The use of urea (at 10% concentration or less) in ointments and creams to treat dry skin has been widespread, and long term follow-up studies have indicated that the substance is nonallergenic and virtually free from side effects. Among other clinical therapeutic uses, the treatment of inappropriate secretion of antidiuretic hormone (SIADH) should be noted, because its chronic form has involved long term oral administration of large amounts of urea. Most patients have tolerated urea well, although diarrhoea is sometimes reported after ingestion of 60-90 g/day. The possibility exists that infection of H. pylori in human stomach may aggravate local effects by urea because of ammonia generation.</p> <p><b>Acute toxicity:</b> The acute toxicity by urea is well delineated by the oral route. Toxicity is low in mammals other than ruminants, especially cattle, and sheep, in which the rumen micro-organisms contain urease activity and metabolise urea to ammonia at a high rate. In mice and rats, urea is of low toxicity even by the subcutaneous and intravenous route.</p> <p><b>Repeated dose toxicity:</b> No well-conducted repeated dose toxicity studies on urea were located. Chronic toxicity and carcinogenicity screening studies in mice and rats fed with 4500, 9000 or 45000 ppm in diet (up to about 6750 mg/kg body weight/day for mice and about 2250 mg/kg body weight/day for rats) did not uncover any treatment-related toxic syndromes in the various organs studied. Neither was any weight depression noted at terminal necropsy for animals of either sex or species at any dose levels. Thus the NOAELs were about 6750 mg/kg body weight/day for mice and about 2250 mg/kg body weight/day for rats.</p> <p>Repeated dose toxicity studies with rats by skin application over 4 weeks and 25 weeks were conducted using urea ointment at 10%, 20% and 40% concentrations, and no consistent treatment-related toxic effects were found. The ointments were applied on a 20 cm<sup>2</sup> area of the back skin; it is concluded that the repeated dose toxicity of urea by dermal route is low.</p> <p><b>Reproductive/developmental toxicity:</b> The studies cited under repeated dose toxicity did not indicate any toxic effects on the reproductive organs of mice and rats. No adequate teratogenicity/developmental toxicity studies of urea with mammals were located. According to one rat study, 50 g/kg body weight/day administered by gavage in two doses 12 hours apart for an average of 14 days did not cause outstanding (external) teratogenicity; the mean birthweight of the newborn was lower but the litter size greater. Injection of urea into the air sack of eggs shows that urea is toxic to the development of chick embryo.</p> <p>No NOAEL can be given for the reproductive/developmental toxicity of urea because appropriate studies are lacking.</p> <p><b>Genetic toxicity:</b> Urea has been negative in several appropriately conducted bacterial mutagenicity tests. Urea caused DNA single strand breaks in mammalian cells in vitro and was clastogenic for mammalian cells in vitro and in vivo but only at concentrations much beyond the physiological range (about 50-100 higher concentrations than found in human blood). The mechanism of genotoxicity is probably non-specific (e.g. difference in osmotic pressure across the cell membrane).</p> <p><b>NOTE:</b> Substance has been shown to be mutagenic in at least one assay, or belongs to a family of chemicals producing damage or change to</p>
------	--

# Advantage CropAmmo

	cellular DNA.
AMMONIUM SULFATE	<p>for ammonium sulfate</p> <p>As ammonium sulfate dissociates in biological systems studies with other ammonium and sulfate salts can be used to cover these endpoints: A screening study according to OECD TG 422 with ammonium phosphate as analogue substance, which forms ammonium ions in aqueous solutions is available. Fully valid fertility studies with analogue compounds containing sulfate ions are however lacking. Two limited studies with sodium sulfate can be used for assessment of fertility and developmental toxicity, however, in none of these studies have the foetuses been examined histologically. There are no in vivo data on genotoxicity for ammonium sulfate. To bridge the data gap, data for ammonium chloride, which dissociates in aqueous media to form ammonium ions, as does ammonium sulfate, will be used.</p> <p>In aqueous media, ammonium sulfate dissociates in the ammonium and sulfate ions (NH<sub>4</sub><sup>+</sup>, SO<sub>4</sub><sup>2-</sup>). These can be taken up into the body by the oral and respiratory routes. Absorbed ammonium is transported to the liver and there metabolised to urea and excreted via the kidneys. Ammonium is also an endogenous substance that serves a major role in the maintenance of the acid-base balance. Minor amounts of ammonium nitrogen are incorporated in the physiological N-pool. Sulfate is a normal intermediate in the metabolism of endogenous sulfur compounds, and is excreted unchanged or in conjugated form in urine.</p> <p><b>Acute toxicity:</b> Ammonium sulfate is of relatively low acute toxicity (LD<sub>50</sub>, oral, rat: 2000 - 4250 mg/kg bw; LD<sub>50</sub> dermal, rat/mouse &gt; 2000 mg/kg bw; 8-h LC<sub>50</sub>, inhalation, rat &gt; 1000 mg/m<sup>3</sup>). Clinical signs after oral exposure included staggering, prostration, apathy, and laboured and irregular breathing immediately after dosing at doses near to or exceeding the LD<sub>50</sub> value. In humans, inhalation exposure to 0.1-0.5 mg ammonium sulfate/m<sup>3</sup> aerosol for two to four hours produced no pulmonary effects. At 1 mg ammonium sulfate/m<sup>3</sup> very slight pulmonary effects in the form of a decrease in expiratory flow, in pulmonary flow resistance and dynamic lung compliance were found in healthy volunteers after acute exposure.</p> <p>Neat ammonium sulfate was not irritating to the skin and eyes of rabbits. There is no data on sensitisation available.</p> <p><b>Repeat dose toxicity:</b> A 14-day inhalation study on rats exposed to 300 mg/m<sup>3</sup>, the only tested dose, did not report histopathological changes in the lower respiratory tract. As the respiratory tract is the target organ for inhalation exposure, the NOEL for toxicity to the lower respiratory tract is 300 mg/m<sup>3</sup>.</p> <p>The NOAEL after feeding diets containing ammonium sulfate for 13 weeks to rats was 886 mg/kg bw/day. The only toxicity sign found was diarrhea in male animals of the high-dose group (LOAEL: 1792 mg/kg bw/day).</p> <p><b>Reproductive toxicity:</b> There are no valid studies available on the effects of ammonium sulfate on fertility and development. Based on data from a similar ammonium compound (diammonium phosphate), which has been tested up to 1500 mg/kg bw in a screening study according to OECD TG 422 in rats it can be concluded that ammonium ions up to the dose tested have no negative effects on fertility. In the 13-week feeding study of ammonium sulfate with rats, no histological changes of testes were observed up to 1792 mg/kg bw. The ovaries were not examined. Fully valid studies with sulfate on fertility are not available.</p> <p>In a limited study (pretreatment time short, low number of animals, no fertility indices measured) where female mice were treated with up to ca. 6550 mg sulfate/kg bw (as sodium sulfate) no effects on litter size were found.</p> <p><b>Developmental toxicity:</b> Studies of developmental toxicity for ammonium sulfate are not available. In the screening study according to OECD TG 422 with up to 1500 mg diammonium phosphate/kg bw no effects on development have been detected in rats. In another limited screening study with exposure of mice to a single dose of 2800 mg sodium sulfate/kg bw no macroscopic effects or adverse effects on body weight gain have been detected in the pups. In both studies foetuses were not examined histopathologically.</p> <p><b>Genotoxicity:</b> Ammonium sulfate was not mutagenic in bacteria (Ames test) and yeasts with and without metabolic activation systems. It did not induce chromosomal aberrations in mammalian or human cell cultures. No in vivo genotoxicity tests are available. Based on the negative results from in vitro studies and the negative results in the micronucleus test in vivo with ammonium chloride a mutagenic activity of ammonium sulfate in vivo is unlikely.</p> <p>Similarly to other salts, high doses of ammonium sulfate may have the capability of tumour promotion in the rat stomach; it is, however, much less potent than sodium chloride when tested under identical conditions.</p>
PROPYLENE GLYCOL	<p>The acute oral toxicity of propylene glycol is very low, and large quantities are required to cause perceptible health damage in humans. Serious toxicity generally occurs only at plasma concentrations over 1 g/L, which requires extremely high intake over a relatively short period of time. It would be nearly impossible to reach toxic levels by consuming foods or supplements, which contain at most 1 g/kg of PG. Cases of propylene glycol poisoning are usually related to either inappropriate intravenous administration or accidental ingestion of large quantities by children. The potential for long-term oral toxicity is also low. Because of its low chronic oral toxicity, propylene glycol was classified by the U. S. Food and Drug Administration as "generally recognized as safe" (GRAS) for use as a direct food additive.</p> <p>Prolonged contact with propylene glycol is essentially non-irritating to the skin. Undiluted propylene glycol is minimally irritating to the eye, and can produce slight transient conjunctivitis (the eye recovers after the exposure is removed). Exposure to mists may cause eye irritation, as well as upper respiratory tract irritation. Inhalation of the propylene glycol vapours appears to present no significant hazard in ordinary applications. However, limited human experience indicates that inhalation of propylene glycol mists could be irritating to some individuals. It is therefore recommended that propylene glycol not be used in applications where inhalation exposure or human eye contact with the spray mists of these materials is likely, such as fogs for theatrical productions or antifreeze solutions for emergency eye wash stations.</p> <p>Propylene glycol is metabolised in the human body into pyruvic acid (a normal part of the glucose-metabolism process, readily converted to energy), acetic acid (handled by ethanol-metabolism), lactic acid (a normal acid generally abundant during digestion), and propionaldehyde (a potentially hazardous substance).</p> <p>Propylene glycol shows no evidence of being a carcinogen or of being genotoxic.</p> <p>Research has suggested that individuals who cannot tolerate propylene glycol probably experience a special form of irritation, but that they only rarely develop allergic contact dermatitis. Other investigators believe that the incidence of allergic contact dermatitis to propylene glycol may be greater than 2% in patients with eczema.</p> <p>One study strongly suggests a connection between airborne concentrations of propylene glycol in houses and development of asthma and allergic reactions, such as rhinitis or hives in children.</p> <p>Another study suggested that the concentrations of PGEs (counted as the sum of propylene glycol and glycol ethers) in indoor air, particularly bedroom air, is linked to increased risk of developing numerous respiratory and immune disorders in children, including asthma, hay fever, eczema, and allergies, with increased risk ranging from 50% to 180%. This concentration has been linked to use of water-based paints and water-based system cleansers.</p> <p>Patients with vulvodynia and interstitial cystitis may be especially sensitive to propylene glycol. Women suffering with yeast infections may also notice that some over the counter creams can cause intense burning. Post menopausal women who require the use of an estrogen cream may notice that brand name creams made with propylene glycol often create extreme, uncomfortable burning along the vulva and perianal area. Additionally, some electronic cigarette users who inhale propylene glycol vapor may experience dryness of the throat or shortness of breath. As an alternative, some suppliers will put Vegetable Glycerin in the "e-liquid" for those who are allergic (or have bad reactions) to propylene glycol.</p> <p>Adverse responses to intravenous administration of drugs which use PG as an excipient have been seen in a number of people, particularly with large dosages thereof. Responses may include "hypotension, bradycardia... QRS and T abnormalities on the ECG, arrhythmia, cardiac arrest, serum hyperosmolality, lactic acidosis, and haemolysis". A high percentage (12% to 42%) of directly-injected propylene glycol is eliminated/secreted in urine unaltered depending on dosage, with the remainder appearing in its glucuronide-form. The speed of renal filtration decreases as dosage increases, which may be due to propylene glycol's mild anesthetic / CNS-depressant -properties as an alcohol. In one case, intravenous administration of propylene glycol-suspended nitroglycerin to an elderly man may have induced coma and acidosis.</p> <p>Propylene glycol is an approved food additive for dog food under the category of animal feed and is generally recognized as safe for dogs with an LD<sub>50</sub> of 9 mL/kg. The LD<sub>50</sub> is higher for most laboratory animals (20 mL/kg).</p> <p>Similarly, propylene glycol is an approved food additive for human food as well. The exception is that it is prohibited for use in food for cats due to links to Heinz body anemia.</p> <p>The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling the epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis.</p>

## Advantage CropAmmo

### N-(N-BUTYL)THIOPHOSPHORIC TRIAMIDE

NOEL (rat): 250 mg/kg/day based on cholinesterase inhibition. Mutagenicity: Ames test: in vitro mammalian cell gene mutation, and in vivo mammalian chromosome damage tests were each negative [Manufacturer] Mild sensitiser

The following information refers to contact allergens as a group and may not be specific to this product.

Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke's oedema. The pathogenesis of contact eczema involves a cell-mediated (T lymphocytes) immune reaction of the delayed type. Other allergic skin reactions, e.g. contact urticaria, involve antibody-mediated immune reactions. The significance of the contact allergen is not simply determined by its sensitisation potential: the distribution of the substance and the opportunities for contact with it are equally important. A weakly sensitising substance which is widely distributed can be a more important allergen than one with stronger sensitising potential with which few individuals come into contact. From a clinical point of view, substances are noteworthy if they produce an allergic test reaction in more than 1% of the persons tested.

Urease inhibitors can induce leaf-tip necrosis in plants. Research to account for this phytotoxicity indicated that it resulted from an accumulation of toxic amounts of urea in plants through inhibition of urease activity. Support for this conclusion was provided by experiments showing that these urease inhibitors increased both leaf-tip necrosis and urea concentrations in wheat (*Triticum aestivum* L.) and sorghum [*Sorghum bicolor* (L.) Moench] plants grown in soils treated with urea and that the necrotic areas of such plants had a much higher concentration of urea than did the nonnecrotic areas. The potential of urease inhibitors for inducing phytotoxicity should not preclude their use to eliminate the adverse effects of urea fertilizers on seed germination and seedling growth in soil because the ammonia produced through hydrolysis of urea fertilizer by urease is much more detrimental to plant growth than is the urea accumulation induced by urease inhibitors.

Clinical studies have shown that the oral administration of the urease inhibitor acetohydroxamic acid can reduce the extent of infection-associated kidney and bladder stone formation and catheter encrustation. However, later studies reported that the acetohydroxamic acid treatment caused intolerable side effects and its use was abandoned. The effects seem to be related to the development of an alkaline microenvironment. Laboratory models were used to examine the effect of the urease inhibitors acetohydroxamic acid and fluorofamide on *P. mirabilis*-induced catheter encrustation. When models were supplied with urine supplemented with acetohydroxamic acid (1.0 mg/ml) or fluorofamide (1.0 µg/ml) the rise in pH was controlled and significantly less deposition of calcium and magnesium salts compared with controls occurred on the catheters.

For dithiophosphate alkyl esters and their (zinc) salts:

**Acute toxicity:** Dithiophosphate alkyl esters consist of a phosphorodithioic acid structure with alkyl ester substituent groups. The alkyl groups are saturated hydrocarbon chains that vary in length and extent of branching. While corrosive to tissue the esters demonstrate a low concern for acute systemic toxicity. Data on acute mammalian toxicity of zinc dialkyldithiophosphates in highly refined lubricant base oil also indicate a low concern for acute toxicity. Commercial oil-based samples of the zinc dialkyldithiophosphate category have been tested for acute oral toxicity. The acute oral LD50 for these studies in rats ranged from 2000-3500 mg/kg. Clinical signs observed following treatment included diarrhea, lethargy, reduced food consumption, and staining about the nose and eye. Ptosis, piloerection, ataxia and salivation were occasionally observed. The incidence and severity of these symptoms were proportional to the dose. In many cases the effects were found to be reversible during observation week 2. Necropsy findings were few in number. Lung congestion, gastrointestinal irritation and a reduction in body fat were observed in some animals.

Acute dermal toxicity and irritation studies using the ester on experimental animals resulted in severe dermal irritation and corrosivity. There is minimal opportunity of human exposure to the chemicals in this category. Dithiophosphate alkyl esters exhibit extreme corrosive properties on skin.

Commercial oil-based samples of the zinc dialkyldithiophosphate category have been tested for acute dermal toxicity. The acute dermal LD50s for these studies in rabbits were greater than 2000 mg/kg (limit tests). No treatment-related mortality was observed at doses ranging from 2000-8000 mg/kg. Dermal application of the test materials to abraded skin for 24 hours typically produced moderate-to-severe erythema and edema, which in some cases persisted through the 14-day observation period. Clinical signs included varying degrees of reduced food consumption, weight loss, diarrhea, lethargy, ataxia, ptosis, motor incoordination and/or loss of righting reflex. There were no remarkable gross necropsy observations. Overall, the acute dermal LD50 for these substances were greater than 2000 mg/kg indicative of a relatively low order of lethal toxicity. Zinc dialkyldithiophosphates are high molecular weight components (average > 500 gm/mol), which generally accepted that the molecular weight limit for passive transport across biological membranes. Thus, upon exposure it is unlikely that significant amounts of these components will be absorbed for systemic distribution. In addition, these materials have a low water solubility that further inhibits absorption and distribution in the mammalian system.

The negligible vapor pressure and high viscosity at ambient temperature indicates that these materials are unlikely to represent an inhalation exposure under conditions of use

**Repeat dose toxicity:** Data from several repeated-dose toxicity studies using commercial samples of zinc dialkyldithiophosphates in highly refined lubricant base oil has been reviewed. Repeated dermal exposure to experimental animals resulted in moderate-to-severe dermal irritation, behavioral distress, body weight loss and emaciation, reduction in hematological parameters and adverse effects on male reproductive organs. These effects were observed across several members of the category with carbon chain lengths ranging from C4-8. There was no evidence that the incremental increase in carbon chain length or molecular weight could be correlated with significant changes in toxicity parameters.

Oral administration caused significant gastric irritation and related gastrointestinal disturbances, signs of distress but with no evidence of adverse effects on male reproductive organs.

**Reproductive toxicity:** An epidemiological study on workers exposed to oil-based zinc dialkyldithiophosphates (range C4-8) in an additive manufacturing plant revealed no adverse effects on worker reproductive health. Review of the available information underscores the similarity of clinical and pathological findings in repeated-dose dermal toxicity studies with C4-10 zinc dialkyldithiophosphates, as well as the absence of reproduction and developmental toxicity and the lack of untoward findings in a human epidemiological investigation. Reproductive organ effects, following dermal application, have been observed in male rabbits; these are attributed to the stress associated with the severe dermal responses to the test material, rather than direct a systemic response to the test materials. Changes in male reproductive organs in the rabbit have been observed when other irritating substances are applied to the skin at dose levels that cause skin lesions. Thus, dermal irritation alone, or in combination with the accompanying weight loss and stress, is thought to play a role in the reproductive organ response to repeated cutaneous application of zinc dialkyldithiophosphates.

**Mutagenicity:** Findings indicate that commercial samples of zinc dialkyldithiophosphates in highly refined lubricant base oil have a small potential for inducing genetic toxicity. In vitro bacterial gene mutation assays, in vitro mammalian gene mutation assays, or in vivo chromosomal aberration assays have been conducted. Frequencies of reverse mutations in bacteria were not significantly changed after exposure to the zinc dialkyldithiophosphates. In vitro mutation studies in mammalian cells indicate that the zinc dialkyldithiophosphates do not consistently display mutagenic activity in the absence of metabolic activation, however, upon biotransformation, these materials showed mutagenic activity. The findings in bacterial and mammalian cells did not vary in proportion to the alkyl chain length or any other physicochemical parameter. The results of the studies performed in the absence of hepatic microsome activation were inconsistent, but in general indicating that zinc dialkyldithiophosphates have mutagenic potential (3 studies negative, 3 studies positive in the absence of metabolic activation). However, the weight of evidence (2 studies positive, 1 study negative) indicates that metabolic activation of zinc dialkyldithiophosphates by induced hepatic microsomal enzymes results in a significant increase in the mutagenic potential of this class of chemical substances.

### N-METHYL-2-PYRROLIDONE

for N-methyl-2-pyrrolidone (NMP):

**Acute toxicity:** In rats, NMP is absorbed rapidly after inhalation, oral, and dermal administration, distributed throughout the organism, and eliminated mainly by hydroxylation to polar compounds, which are excreted via urine. About 80% of the administered dose is excreted as NMP and NMP metabolites within 24 h. A probably dose-dependent yellow coloration of the urine in rodents is observed. The major metabolite is 5-hydroxy-N-methyl-2-pyrrolidone.

Studies in humans show comparable results. Dermal penetration through human skin has been shown to be very rapid. NMP is rapidly biotransformed by hydroxylation to 5-hydroxy-N-methyl-2-pyrrolidone, which is further oxidized to N-methylsuccinimide; this intermediate is further hydroxylated to 2-hydroxy-N-methylsuccinimide. These metabolites are all colourless. The excreted amounts of NMP metabolites in the urine after inhalation or oral intake represented about 100% and 65% of the administered doses, respectively.

NMP has a low potential for skin irritation and a moderate potential for eye irritation in rabbits. Repeated daily doses of 450 mg/kg body weight administered to the skin caused painful and severe haemorrhage and eschar formation in rabbits. These adverse effects have not been seen in

## Advantage CropAmmo

workers occupationally exposed to pure NMP, but they have been observed after dermal exposure to NMP used in cleaning processes. No sensitisation potential has been observed.

In acute toxicity studies in rodents, NMP showed low toxicity. Uptake of oral, dermal, or inhaled acutely toxic doses causes functional disturbances and depressions in the central nervous system. Local irritation effects were observed in the respiratory tract when NMP was inhaled and in the pyloric and gastrointestinal tracts after oral administration. In humans, there was no irritative effect in the respiratory system after an 8-h exposure to 50 mg/m<sup>3</sup>.

**Repeat dose toxicity:** There is no clear toxicity profile of NMP after multiple administration. In a 28-day dietary study in rats, a compound-related decrease in body weight gain was observed in males at 1234 mg/kg body weight and in females at 2268 mg/kg body weight. Testicular degeneration and atrophy in males and thymic atrophy in females were observed at these dose levels. The no-observed-adverse-effect level (NOAEL) was 429 mg/kg body weight in males and 1548 mg/kg body weight in females. In a 28-day intubation study in rats, a dose-dependent increase in relative liver and kidney weights and a decrease in lymphocyte count in both sexes were observed at 1028 mg/kg body weight. The NOAEL in this study was 514 mg/kg body weight. In another rat study, daily dietary intake for 90 days caused decreased body weights at doses of 433 and 565 mg/kg body weight in males and females, respectively. There were also neurobehavioural effects at these dose levels. The NOAELs in males and females were 169 and 217 mg/kg body weight, respectively.

The toxicity profile after exposure to airborne NMP depends strongly on the ratio of vapour to aerosol and on the area of exposure (i.e., head-only or whole-body exposure). Because of higher skin absorption for the aerosol, uptake is higher in animals exposed to aerosol than in those exposed to vapour at similar concentrations. Studies in female rats exposed head only to 1000 mg/m<sup>3</sup> showed only minor nasal irritation, but massive mortality and severe effects on major organs were observed when the females were whole-body exposed to the same concentration of coarse droplets at high relative humidity. Several studies in rats following repeated exposure to NMP at concentrations between 100 and 1000 mg/m<sup>3</sup> have shown systemic toxicity effects at the lower dose levels. In most of the studies, the effects were not observed after a 4-week observation period.

In rats, exposure to 3000 mg NMP/m<sup>3</sup> (head only) for 6 h/day, 5 days/week, for 13 weeks caused a decrease in body weight gain, an increase in erythrocytes, haemoglobin, haematocrit, and mean corpuscular volume, decreased absolute testis weight, and cell loss in the germinal epithelium of the testes. The NOAEL was 500 mg/m<sup>3</sup>.

There are no data in humans after repeated-dose exposure.

**Carcinogenicity:** NMP did not show any clear evidence for carcinogenicity in rats exposed to concentrations up to 400 mg/m<sup>3</sup> in a long-term inhalation study.

**Genotoxicity:** The mutagenic potential of NMP is weak. Only a slight increase in the number of revertants was observed when tested in a *Salmonella* assay with base-pair substitution strains. NMP has been shown to induce aneuploidy in yeast *Saccharomyces cerevisiae* cells. No investigations regarding mutagenicity in humans were available.

**Reproductive toxicity:** In a two-generation reproduction study in rats, whole-body exposure of both males and females to 478 mg/m<sup>3</sup> of NMP vapour for 6 h/day, 7 days/week, for a minimum of 100 days (pre-mating, mating, gestation, and lactation periods) resulted in a 7% decrease in fetal weight in the F1 offspring. A 4-11% transient, non-dose-dependent decrease was observed in the average pup weight at all exposure levels tested (41, 206, and 478 mg/m<sup>3</sup>).

**Developmental toxicity:** When NMP was administered dermally, developmental toxicity was registered in rats at 750 mg/kg body weight. The observed effects were increased preimplantation losses, decreased fetal weights, and delayed ossification. The NOAEL for both developmental effects and maternal toxicity (decreased body weight gain) was 237 mg/kg body weight.

Inhalation studies in rats (whole-body exposure) demonstrated developmental toxicity as increased preimplantation loss without significant effect on implantation rate or number of live fetuses at 680 mg/m<sup>3</sup> and behavioural developmental toxicity at 622 mg/m<sup>3</sup>. In an inhalation study (whole-body exposure), the NOAEL for maternal effects was 100 mg/m<sup>3</sup>, and the NOAEL for developmental effects was 360 mg/m<sup>3</sup>.

A tolerable inhalation concentration, 0.3 mg/m<sup>3</sup>, based on mortality and organ damage, is expected to be protective against any possible reproductive toxicity. Similarly, an oral tolerable intake of 0.6 mg/kg body weight per day, based on a 90-day study, is expected to provide adequate protection against possible reproductive effects. Because of non-existent data on the exposure of the general population and very limited information on occupational exposure, no meaningful risk characterisation can be performed.

A substance (or part of a group of chemical substances) of very high concern (SVHC) - or product containing an SVHC:

It is proposed that use within the European Union be subject to authorisation under the REACH Regulation. Indeed, listing of a substance as an SVHC by the European Chemicals Agency (ECHA) is the first step in the procedure for authorisation or restriction of use of a chemical.

The criteria are given in article 57 of the REACH Regulation. A substance may be proposed as an SVHC if it meets one or more of the following criteria:

- ▶ it is carcinogenic \*;
- ▶ it is mutagenic \*;
- ▶ it is toxic for reproduction \*;
- ▶ it is persistent, bioaccumulative and toxic (PBT substances);
- ▶ it is very persistent and very bioaccumulative (vPvB substances);
- ▶ there is "scientific evidence of probable serious effects to human health or the environment which give rise to an equivalent level of concern"; such substances are identified on a case-by-case basis.

\* Collectively described as CMR substances

The "equivalent concern" criterion is significant because it is this classification which allows substances which are, for example, neurotoxic, endocrine-disrupting or otherwise present an unanticipated environmental health risk to be regulated under REACH]



Simply because a substance meets one or more of the criteria does not necessarily mean that it will be proposed as an SVHC. Many such substances are already subject to restrictions on their use within the European Union, such as those in Annex XVII of the REACH Regulation. SVHCs are substances for which the current restrictions on use (where these exist) might be insufficient. There are three priority groups for assessment:

- ▶ PBT substances and vPvB substances;
- ▶ substances which are widely dispersed during use;
- ▶ substances which are used in large quantities.

### UREA & AMMONIUM SULFATE & N-(N-BUTYL)THIOPHOSPHORIC TRIAMIDE & N-METHYL- 2-PYRROLIDONE

Asthma-like symptoms may continue for months or even years after exposure to the material ceases. This may be due to a non-allergenic condition known as reactive airways dysfunction syndrome (RADS) which can occur following exposure to high levels of highly irritating compound. Key criteria for the diagnosis of RADS include the absence of preceding respiratory disease, in a non-atopic individual, with abrupt onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. A reversible airflow pattern, on spirometry, with the presence of moderate to severe bronchial hyperreactivity on methacholine challenge testing and the lack of minimal lymphocytic inflammation, without eosinophilia, have also been included in the criteria for diagnosis of RADS. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. Industrial bronchitis, on the other hand, is a disorder that occurs as result of exposure due to high concentrations of irritating substance (often particulate in nature) and is completely reversible after exposure ceases. The disorder is characterised by dyspnea, cough and mucus production.

Acute Toxicity	✓	Carcinogenicity	✗
Skin Irritation/Corrosion	✗	Reproductivity	✓
Serious Eye Damage/Irritation	✓	STOT - Single Exposure	✗
Respiratory or Skin sensitisation	✓	STOT - Repeated Exposure	✗
Mutagenicity	✗	Aspiration Hazard	✗

**Legenda:**  – Data either not available or does not fulfil the criteria for classification  
 – Data available to make classification

## SECTION 12 Ecological information

### Toxicity

Advantage CropAmmo	Endpoint	Test Duration (hr)	Species	Value	Source
	Not Available	Not Available	Not Available	Not Available	Not Available
urea	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	168h	Fish	200mg/l	2
	LC50	96h	Fish	>1000mg/l	4
	EC50	48h	Crustacea	6119-7061mg/l	4
ammonium sulfate	Endpoint	Test Duration (hr)	Species	Value	Source
	EC50(ECx)	24h	Fish	0.068mg/L	5
	EC50	72h	Algae or other aquatic plants	190mg/l	2
	LC50	96h	Fish	34.6mg/l	2
	EC50	48h	Crustacea	60mg/l	2
propylene glycol	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	336h	Algae or other aquatic plants	<5300mg/l	1
	EC50	72h	Algae or other aquatic plants	19300mg/l	2
	LC50	96h	Fish	>10000mg/l	2
	EC50	48h	Crustacea	>114.4mg/L	4
N-(n-butyl)thiophosphoric triamide	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	96h	Algae or other aquatic plants	75mg/l	2
	EC50	72h	Algae or other aquatic plants	530mg/l	2
	LC50	96h	Fish	1140mg/l	2
	EC50	96h	Algae or other aquatic plants	280mg/l	2
N-methyl-2-pyrrolidone	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	504h	Crustacea	12.5mg/l	2
	EC50	72h	Algae or other aquatic plants	>500mg/l	1
	LC50	96h	Fish	464mg/l	1
N-methyl-2-pyrrolidone	Endpoint	Test Duration (hr)	Species	Value	Source
	EC50	48h	Crustacea	ca.4897mg/l	1

**Legend:** Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 3. EPIWIN Suite V3.12 (QSAR) - Aquatic Toxicity Data (Estimated) 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data

**DO NOT** discharge into sewer or waterways.

### Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
urea	LOW	LOW
ammonium sulfate	HIGH	HIGH
propylene glycol	LOW	LOW
N-(n-butyl)thiophosphoric triamide	HIGH	HIGH
N-methyl-2-pyrrolidone	LOW	LOW

### Bioaccumulative potential

Ingredient	Bioaccumulation
urea	LOW (BCF = 10)
ammonium sulfate	LOW (LogKOW = -2.2002)
propylene glycol	LOW (BCF = 1)
N-(n-butyl)thiophosphoric triamide	LOW (LogKOW = -0.3192)
N-methyl-2-pyrrolidone	LOW (BCF = 0.16)

### Mobility in soil

Continued...



## Advantage CropAmmo

Ingredient	Mobility
urea	LOW (KOC = 4.191)
ammonium sulfate	LOW (KOC = 6.124)
propylene glycol	HIGH (KOC = 1)
N-(n-butyl)thiophosphoric triamide	LOW (KOC = 24.83)
N-methyl-2-pyrrolidone	LOW (KOC = 20.94)

## SECTION 13 Disposal considerations

## Waste treatment methods

Product / Packaging disposal	<ul style="list-style-type: none"> <li>DO NOT allow wash water from cleaning or process equipment to enter drains.</li> <li>It may be necessary to collect all wash water for treatment before disposal.</li> <li>In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first.</li> <li>Where in doubt contact the responsible authority.</li> </ul>
------------------------------	---

Ensure that the hazardous substance is disposed in accordance with the Hazardous Substances (Disposal) Notice 2017

## Disposal Requirements

Packages that have been in direct contact with the hazardous substance must be only disposed if the hazardous substance was appropriately removed and cleaned out from the package. The package must be disposed according to the manufacturer's directions taking into account the material it is made of. Packages which hazardous content have been appropriately treated and removed may be recycled.

The hazardous substance must only be disposed if it has been treated by a method that changed the characteristics or composition of the substance and it is no longer hazardous. Only dispose to the environment if a tolerable exposure limit has been set for the substance.

Only deposit the hazardous substance into or onto a landfill or sewage facility or incinerator, where the hazardous substance can be handled and treated appropriately.

## SECTION 14 Transport information

## Labels Required

Marine Pollutant	NO
HAZCHEM	Not Applicable

Land transport (UN): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
urea	Not Available
ammonium sulfate	Not Available
propylene glycol	Not Available
N-(n-butyl)thiophosphoric triamide	Not Available
N-methyl-2-pyrrolidone	Not Available

Transport in bulk in accordance with the ICG Code

Product name	Ship Type
urea	Not Available
ammonium sulfate	Not Available
propylene glycol	Not Available
N-(n-butyl)thiophosphoric triamide	Not Available
N-methyl-2-pyrrolidone	Not Available

## SECTION 15 Regulatory information

## Safety, health and environmental regulations / legislation specific for the substance or mixture

This substance is to be managed using the conditions specified in an applicable Group Standard

HSR Number	Group Standard
HSR002571	Fertilisers Subsidiary Hazard Group Standard 2020

Please refer to Section 8 of the SDS for any applicable tolerable exposure limit or Section 12 for environmental exposure limit.

urea is found on the following regulatory lists

Continued...

New Zealand Approved Hazardous Substances with controls New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals	New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals - Classification Data New Zealand Inventory of Chemicals (NZIoC)
<b>ammonium sulfate is found on the following regulatory lists</b> New Zealand Approved Hazardous Substances with controls New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals	New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals - Classification Data New Zealand Inventory of Chemicals (NZIoC)
<b>propylene glycol is found on the following regulatory lists</b> New Zealand Approved Hazardous Substances with controls New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals - Classification Data	New Zealand Inventory of Chemicals (NZIoC) New Zealand Workplace Exposure Standards (WES)
<b>N-(n-butyl)thiophosphoric triamide is found on the following regulatory lists</b> New Zealand Inventory of Chemicals (NZIoC)	
<b>N-methyl-2-pyrrolidone is found on the following regulatory lists</b> Chemical Footprint Project - Chemicals of High Concern List New Zealand Approved Hazardous Substances with controls New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals	New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals - Classification Data New Zealand Inventory of Chemicals (NZIoC) New Zealand Workplace Exposure Standards (WES)

Hazardous Substance Location

Subject to the Health and Safety at Work (Hazardous Substances) Regulations 2017.

Hazard Class	Quantities
Not Applicable	Not Applicable

Certified Handler

Subject to Part 4 of the Health and Safety at Work (Hazardous Substances) Regulations 2017.

Class of substance	Quantities
Not Applicable	Not Applicable

Refer Group Standards for further information

Maximum quantities of certain hazardous substances permitted on passenger service vehicles

Subject to Regulation 13.14 of the Health and Safety at Work (Hazardous Substances) Regulations 2017.

Hazard Class	Gas (aggregate water capacity in mL)	Liquid (L)	Solid (kg)	Maximum quantity per package for each classification
6.5A or 6.5B	120	1	3	

Tracking Requirements

Not Applicable

National Inventory Status

National Inventory	Status
Australia - AIIC / Australia Non-Industrial Use	Yes
Canada - DSL	Yes
Canada - NDSL	No (urea; ammonium sulfate; propylene glycol; N-(n-butyl)thiophosphoric triamide; N-methyl-2-pyrrolidone)
China - IECSC	No (N-(n-butyl)thiophosphoric triamide)
Europe - EINEC / ELINCS / NLP	Yes
Japan - ENCS	No (N-(n-butyl)thiophosphoric triamide)
Korea - KECI	Yes
New Zealand - NZIoC	Yes
Philippines - PICCS	No (N-(n-butyl)thiophosphoric triamide)
USA - TSCA	Yes
Taiwan - TCSI	No (N-(n-butyl)thiophosphoric triamide)
Mexico - INSQ	No (N-(n-butyl)thiophosphoric triamide)
Vietnam - NCI	Yes
Russia - FBEPH	No (N-(n-butyl)thiophosphoric triamide)
<b>Legend:</b>	Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory and are not exempt from listing(see specific ingredients in brackets)

SECTION 16 Other information

Revision Date	21/06/2021
Initial Date	21/06/2021



**SDS Version Summary**

Version	Date of Update	Sections Updated
2.1.2.1	29/04/2021	Regulation Change
2.1.2.2	30/05/2021	Template Change
2.1.2.3	04/06/2021	Template Change
2.1.2.4	05/06/2021	Template Change
2.1.2.5	09/06/2021	Template Change
2.1.2.6	11/06/2021	Template Change
2.1.3.6	14/06/2021	Regulation Change
2.1.3.7	15/06/2021	Template Change
2.1.3.7	21/06/2021	Ingredients

**Other information**

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

**Definitions and abbreviations**

PC—TWA: Permissible Concentration-Time Weighted Average  
PC—STEL: Permissible Concentration-Short Term Exposure Limit  
IARC: International Agency for Research on Cancer  
ACGIH: American Conference of Governmental Industrial Hygienists  
STEL: Short Term Exposure Limit  
TEEL: Temporary Emergency Exposure Limit.  
IDLH: Immediately Dangerous to Life or Health Concentrations  
ES: Exposure Standard  
OSF: Odour Safety Factor  
NOAEL :No Observed Adverse Effect Level  
LOAEL: Lowest Observed Adverse Effect Level  
TLV: Threshold Limit Value  
LOD: Limit Of Detection  
OTV: Odour Threshold Value  
BCF: BioConcentration Factors  
BEI: Biological Exposure Index  
AIIIC: Australian Inventory of Industrial Chemicals  
DSL: Domestic Substances List  
NDSL: Non-Domestic Substances List  
IECSC: Inventory of Existing Chemical Substance in China  
EINECS: European INventory of Existing Commercial chemical Substances  
ELINCS: European List of Notified Chemical Substances  
NLP: No-Longer Polymers  
ENCS: Existing and New Chemical Substances Inventory  
KECI: Korea Existing Chemicals Inventory  
NZIoC: New Zealand Inventory of Chemicals  
PICCS: Philippine Inventory of Chemicals and Chemical Substances  
TSCA: Toxic Substances Control Act  
TCSI: Taiwan Chemical Substance Inventory  
INSQ: Inventario Nacional de Sustancias Químicas  
NCI: National Chemical Inventory  
FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.

TEL (+61 3) 9572 4700.